LEXXW News and Press, Lexaria Bioscience Corp. Warrant From 11/28/23

DehydraTECH TM -powered semaglutide achieved these benefits in a human pilot study compared to Rybelsus ® : Sustained lower levels of blood glucose from baseline including nearly 10x lower after 24 hours; Lower blood-glucose spike after eating; and Successful first-ever D...

Lexaria Bioscience (NASDAQ: LEXX, LEXXW) , a global innovator in drug delivery platforms, today announced positive interim results from a human pilot study currently underway evaluating DehydraTECH(TM) technology for the oral delivery of the glucagon-like peptide-1 (“GLP-1”) drug se...

(TheNewswire) DehydraTECH TM -powered semaglutide achieved these benefits in a human pilot study compared to Rybelsus ® : Sustained higher levels of semaglutide in blood; Faster achievement of peak drug delivery; and Reduced side effe...

Lexaria Bioscience (NASDAQ: LEXX, LEXXW) , a global innovator in drug-delivery platforms, has granted a new global, exclusive license to SulfoSyn Limited; the license is for the exclusive global use of all nonpharmaceutical applications of Lexaria’s proprietary DehydraTECH-sulforaphane, in...

Global exclusivity for all non-pharmaceutical applications of DehydraTECH-sulforaphane has been awarded Minimum ongoing payments, royalties and manufacturing revenues part of the agreement KELOWNA, BC / ACCESSWIRE / October 13, 2023 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXX...

Lexaria Bioscience (NASDAQ: LEXX, LEXXW) , a global innovator in drug delivery platforms, today announced that it has been granted two new patents by the Canadian Intellectual Property Office (“CIPO”), increasing its portfolio to 37 granted patents. According to the update, Canadian...

Lexaria now holds 37 granted patents world-wide Potential application in treating nicotine addiction KELOWNA, BC / ACCESSWIRE / October 12, 2023 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces ...

Lexaria Bioscience (NASDAQ: LEXX, LEXXW) , a global innovator in drug-delivery platforms, has entered into a securities purchase agreement with a single healthcare-focused institutional investor; the agreement is for the purchase of 1,618,330 shares of common stock (or pre-funded warrants in lieu...

KELOWNA, BC / ACCESSWIRE / September 29, 2023 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today announced that it has entered into a securities purchase agreement with a single healthcare-focused institutiona...

Lexaria Bioscience (NASDAQ: LEXX, LEXXW) , a global innovator in drug delivery platforms, today announced its intention to launch new human and animal studies to examine DehydraTECH(TM)-processed glucagon-like peptide-1 (“GLP-1”) drugs such as, but not limited to, semaglutide sold u...